| Literature DB >> 28033338 |
Seong Jin Choi1, Sang-Won Park1,2, In-Gyu Bae3, Sung-Han Kim4, Seong Yeol Ryu5, Hyun Ah Kim5, Hee-Chang Jang6, Jian Hur7, Jae-Bum Jun8, Younghee Jung9, Hyun-Ha Chang10, Young Keun Kim11, Jongyoun Yi12, Kye-Hyung Kim13, Jeong-Hwan Hwang14, Yeon-Sook Kim15, Hye Won Jeong16, Kyoung-Ho Song1,17, Wan Beom Park1, Eu Suk Kim1,17, Myoung-Don Oh1.
Abstract
BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease that was recently identified in China, South Korea and Japan. The objective of the study was to evaluate the epidemiologic and clinical characteristics of SFTS in South Korea. METHODS/PRINCIPALEntities:
Mesh:
Substances:
Year: 2016 PMID: 28033338 PMCID: PMC5226827 DOI: 10.1371/journal.pntd.0005264
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Temporal distribution of 172 patients with severe fever with thrombocytopenia syndrome (SFTS) in South Korea, 2013–2015.
The main epidemic period of SFTS was May to October. No cases were reported from December to March, which is the winter season.
Fig 2Geographic distribution of 172 patients with severe fever with thrombocytopenia syndrome (SFTS) in South Korea, 2013–2015.
SFTS occurred throughout the country with the exception of urban areas. The incidence was relatively low in the western and southwestern rice field areas and the scarcely populated eastern mountainous areas. Hilly areas were the major endemic regions. Orange circles indicate the site of infection, and the size of the circle represents the number of SFTS cases by area. Shading indicates cases per 100,000 persons.
Baseline characteristics of patients with severe fever with thrombocytopenia syndrome in South Korea, 2013–2015.
| No. (%) | |||||
|---|---|---|---|---|---|
| Characteristics | Non-fatal | Fatal | Total | ||
| (n = 74) | (n = 46) | (n = 120) | |||
| Sex | |||||
| Male | 42 (56.8) | 19 (41.3) | 61 (50.8) | 0.100 | |
| Female | 32 (43.2) | 27 (58.7) | 59 (49.2) | ||
| Age, years (median; IQR) | 66 (52–74) | 73.5 (66–79) | 69 (59–77) | <0.001 | |
| Occupation | |||||
| Farmers | 26 (38.2) | 26 (59.1) | 52 (46.4) | 0.031 | |
| Non-farmers | 42 (61.7) | 18 (40.9) | 60 (53.6) | ||
| Tick bite | |||||
| Memory of tick bite | 15 (20.8) | 11 (23.9) | 26 (22.0) | 0.694 | |
| Presence of bite wound | 21 (28.8) | 15 (32.6) | 36 (30.3) | 0.657 | |
| Complications | |||||
| Meningoencephalitis | 11 (15.1) | 5 (11.6) | 16 (13.8) | 0.604 | |
| Mechanical ventilation | 6 (8.1) | 31 (68.9) | 37 (31.1) | <0.001 | |
| Myocarditis | 2 (2.7) | 3 (6.7) | 5 (4.2) | 0.365 | |
| Arrhythmia | 3 (4.1) | 11 (24.4) | 14 (11.8) | 0.002 | |
| Acute kidney injury | 3 (4.1) | 14 (43.8) | 17 (14.2) | <0.001 | |
| Other | 1 (1.4) | 5 (10.9) | 6 (5.0) | 0.030 | |
| Comorbidity | |||||
| DM | 12 (16.2) | 10 (22.2) | 22 (18.5) | 0.413 | |
| HTN | 19 (25.7) | 19 (41.3) | 38 (31.7) | 0.074 | |
| CVA | 2 (2.7) | 3 (6.5) | 5 (4.2) | 0.370 | |
| CHF | 1 (1.4) | 1 (2.2) | 2 (1.7) | 1.000 | |
| CLD | 1 (1.4) | 1 (2.2) | 2 (1.7) | 1.000 | |
| CKD | 0 (0) | 0 (0) | 0 (0) | ||
| Asthma | 2 (2.7) | 1 (2.2) | 3 (2.5) | 1.000 | |
| COPD | 1 (1.4) | 1 (2.2) | 2 (1.7) | 1.000 | |
| Solid tumor | 2 (2.7) | 1 (2.2) | 3 (2.5) | 1.000 | |
| No comorbidity | 42 (56.8) | 22 (47.8) | 64 (53.3) | 0.340 | |
| Onset of illness to admission | 4 (3–6) | 4 (2–5) | 4 (3–6) | 0.500 | |
| (median days, IQR) | |||||
aOther complications include rhabdomyolysis and subdural hemorrhage.
IQR: interquartile range, DM: diabetes mellitus, HTN: hypertension, CVA: cerebrovascular accident, CHF: congestive heart failure, CLD: chronic liver disease, CKD: chronic kidney diseases, COPD: chronic obstructive pulmonary disease.
Fig 3Changes in laboratory parameters over time by intervals of 3 days in 120 patients with severe fever with thrombocytopenia syndrome.
The Y-axis values denote the mean and 95% confidence intervals. Blue and red lines indicate the non-fatal and fatal groups, respectively. The number in parenthesis shows non-fatal (blue) and fatal (red) patients included in the analysis at each time point. P values show the statistical significance of variables at each time point over 3 weeks between the two groups. WBC, white blood cell; Hb, hemoglobin; ALP, serum alkaline phosphatase; AST, serum aspartate aminotransferase; ALT, serum alanine aminotransferase; PT, prothrombin time; aPTT, activated partial thromboplastin time; CRP, C-reactive protein.
Risk factors of mortality in the 1st week after the onset of illness in SFTS.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variable | OR | 95% CI | Adjusted OR | 95% CI | ||
| Sex (female) | 2.53 | 1.08–6.18 | 3.60 | 1.01–15.14 | 0.052 | |
| Age | 4.00 | 1.57–11.28 | ||||
| Dyspnea | 5.26 | 1.83–16.75 | ||||
| GI bleeding | 5.89 | 1.27–52.04 | ||||
| Confusion | 9.03 | 3.19–28.79 | 8.48 | 2.16–40.90 | ||
| Leukopenia (<4,000/mm3) | 4.52 | 0.76–86.69 | 0.167 | |||
| Anemia (<11 g/dL) | 3.86 | 1.42–11.12 | ||||
| Thrombocytopenia (<50×103/mm3) | 3.16 | 1.31–8.08 | 3.13 | 0.87–12.78 | 0.090 | |
| Elevated ALP (>120 IU/L) | 3.29 | 1.31–8.59 | ||||
| Elevated AST (≥400 IU/L) | 3.29 | 1.24–9.91 | ||||
| Elevated ALT (≥200 IU/L) | 3.81 | 1.45–10.55 | ||||
| Elevated CRP (mg/dL) | 1.20 | 1.04–1.46 | 1.23 | 1.03–1.54 | ||
| PT prolongation (INR ≥1.3) | 7.97 | 2.24–37.79 | ||||
| aPTT prolongation (≥60 sec) | 4.29 | 1.70–11.38 | 4.53 | 1.33–16.57 | ||
GI: gastrointestinal, ALP: alkaline phosphatase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, PT: prothrombin time, aPTT: activated partial thromboplastin time, CRP: C-reactive protein, OR: odds ratio